Chaccour, CarlosCasellas, AinaBlanco-Di Matteo, AndrésPineda, IñigoFernández Montero, AlejandroRuiz Castillo, PaulaRichardson, Mary-AnnRodríguez Mateos, MarianoJordán Iborra, CarlotaBrew, JoeCarmona Torre, FranciscoGiráldez, MiriamLaso, EsterDobaño, Carlota, 1969-Moncunill Piñas, GemmaYuste, José R.Pozo, José Luis delRabinovich, ReginaSchöning, VerenaHammann, FelixReina, GabrielSadaba, BelenFernández Alonso, Miriam2021-01-182021-01-182021-01https://hdl.handle.net/2445/173199Dades primàries associades a l'article publicat a EClinicalMedicine, vol. 32 [https://doi.org./10.1016/j.eclinm.2020.100720]The trial was conducted in the Pamplona metropolitan area (Navarra, Spain). Patients were enrolled between July 31, 2020 and September 11, 2020 and randomized in a 1:1 ratio to ivermectin (400 mcg/kg) single oral dose or placebo. Assessments on enrollment and at days 4, 7, 14, 21 and 28 post treatment included: general symptoms report, physical examination and adverse events. All patients were asked to complete a daily online diary of symptoms from day 1 to 28 post treatment. On enrollment, as well as on days 7 and 14 blood samples were obtained to assess full blood count, C reactive protein, procalcitonin, ferritin, creatinine phosphokinase, lactic dehydrogenase, troponin T, D dimer, IL-6, and renal function. Viral loads were calculated at enrollment and on days 4, 7, 14 and 21 post treatment based on a nasopharyngeal swab for SARS-CoV-2 PCR (for genes N and E). A semi-quantitative serology for IgG against SARS-CoV-2 was done on samples from all patients on day 21 post-treatment.text/csvengcc-by (c) Chaccour et al., 2020http://creativecommons.org/licenses/by/3.0/es/Assaigs clínicsCOVID-19TerapèuticaPamplona (Navarra)Clinical trialsCOVID-19TherapeuticsPamplona (Navarra)info:eu-repo/semantics/datasetinfo:eu-repo/semantics/openAccess